Literature DB >> 12197664

Molecular docking studies of a group of hydroxamate inhibitors with gelatinase-A by molecular dynamics.

Tingjun Hou1, Wei Zhang, Xiaojie Xu.   

Abstract

We have performed docking and molecular dynamics simulations of hydroxamates complexed with human gelatinase-A (MMP-2) to gain insight into the structural and energetic preferences of these inhibitors. The study was conducted on a selected set of eleven compounds with variation in structure and activity. Molecular dynamics simulations were performed at 300 K for 100 ps with equilibration for 50 ps. The structural analyses of the trajectories indicate that the coordinate bond interactions, the hydrogen bond interactions, the van der Waals interactions as well as the hydrophobic interactions between ligand and receptor are responsible simultaneously for the preference of inhibition and potency. The ligand hydroxamate group is coordinated to the catalytic zinc ion and form stable hydrogen bonds with the carbonyl oxygen of Gly 162. The P1' group makes extensive van der Waals and hydrophobic contacts with the nonpolar side chains of several residues in the S1' subsite, including Leu 197, Val 198, Leu 218 and Tyr 223. Moreover, four to eight hydrogen bonds between hydroxamates and MMP-2 are formed to stabilize the inhibitors in the active site. Compared with the P2' and P3' groups, the P1' groups of inhibitors are oriented regularly, which is produced by the restrain of the S1' subsite. From the relationship between the length of the nonpolar P1' group and the biological activity, we confirm that MMP-2 has a pocket-like S1' subsite, not a channel-like S1' subsite proposed by Kiyama (Kiyama, R. et al., J. Med. Chem. 42 (1999), 1723). The energetic analyses show that the experimental binding free energies can be well correlated with the interactions between the inhibitors and their environments, which could be used as a simple score function to evaluate the binding affinities for other similar hydroxamates. The validity of the force field parameters and the MD simulations can be fully testified by the satisfactory agreements between the experimental structure-activity relationship and the information from the structural and energetic analyses. The information generated from the predicted complexes should be useful for further work in the area of structure-based design of new compounds.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12197664     DOI: 10.1023/a:1016345810973

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  23 in total

1.  Binding preferences of hydroxamate inhibitors of the matrix metalloproteinase human fibroblast collagenase.

Authors:  S Toba; K V Damodaran; K M Merz
Journal:  J Med Chem       Date:  1999-04-08       Impact factor: 7.446

2.  Design and therapeutic application of matrix metalloproteinase inhibitors.

Authors:  M Whittaker; C D Floyd; P Brown; A J Gearing
Journal:  Chem Rev       Date:  1999-09-08       Impact factor: 60.622

Review 3.  Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation.

Authors:  L A Liotta; P S Steeg; W G Stetler-Stevenson
Journal:  Cell       Date:  1991-01-25       Impact factor: 41.582

Review 4.  Matrix metalloproteinases and their inhibitors in connective tissue remodeling.

Authors:  J F Woessner
Journal:  FASEB J       Date:  1991-05       Impact factor: 5.191

Review 5.  Human matrix metalloproteinase specificity studies using collagen sequence-based synthetic peptides.

Authors:  H Nagase; G B Fields
Journal:  Biopolymers       Date:  1996       Impact factor: 2.505

6.  Astacins, serralysins, snake venom and matrix metalloproteinases exhibit identical zinc-binding environments (HEXXHXXGXXH and Met-turn) and topologies and should be grouped into a common family, the 'metzincins'.

Authors:  W Bode; F X Gomis-Rüth; W Stöckler
Journal:  FEBS Lett       Date:  1993-09-27       Impact factor: 4.124

Review 7.  Matrix metalloproteinases: a review.

Authors:  H Birkedal-Hansen; W G Moore; M K Bodden; L J Windsor; B Birkedal-Hansen; A DeCarlo; J A Engler
Journal:  Crit Rev Oral Biol Med       Date:  1993

8.  Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4.

Authors:  J Greene; M Wang; Y E Liu; L A Raymond; C Rosen; Y E Shi
Journal:  J Biol Chem       Date:  1996-11-29       Impact factor: 5.157

Review 9.  The metzincins--topological and sequential relations between the astacins, adamalysins, serralysins, and matrixins (collagenases) define a superfamily of zinc-peptidases.

Authors:  W Stöcker; F Grams; U Baumann; P Reinemer; F X Gomis-Rüth; D B McKay; W Bode
Journal:  Protein Sci       Date:  1995-05       Impact factor: 6.725

Review 10.  Structure-function relationships in the tissue inhibitors of metalloproteinases.

Authors:  F Willenbrock; G Murphy
Journal:  Am J Respir Crit Care Med       Date:  1994-12       Impact factor: 21.405

View more
  2 in total

1.  Molecular dynamics simulation of matrix metalloproteinase 2: fluctuations and time evolution of recognition pockets.

Authors:  Mattia Falconi; Gioia Altobelli; Maria Cristina Iovino; Vincenzo Politi; Alessandro Desideria
Journal:  J Comput Aided Mol Des       Date:  2003-12       Impact factor: 3.686

2.  Binding affinity of hydroxamate inhibitors of matrix metalloproteinase-2.

Authors:  Wei Zhang; Ting-Jun Hou; Xue Bin Qiao; Sun Huai; Xiao Jie Xu
Journal:  J Mol Model       Date:  2004-02-21       Impact factor: 1.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.